196 related articles for article (PubMed ID: 17020954)
1. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies.
Webster R; Didier E; Harris P; Siegel N; Stadler J; Tilbury L; Smith D
Drug Metab Dispos; 2007 Jan; 35(1):9-16. PubMed ID: 17020954
[TBL] [Abstract][Full Text] [Related]
2. Final report on the safety assessment of Triethylene Glycol and PEG-4.
Int J Toxicol; 2006; 25 Suppl 2():121-38. PubMed ID: 17090481
[TBL] [Abstract][Full Text] [Related]
3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of free polyethylene glycol in PEGylated protein conjugate by size exclusion HPLC with refractive index (RI) detection.
Li N; Ziegemeier D; Bass L; Wang W
J Pharm Biomed Anal; 2008 Dec; 48(5):1332-8. PubMed ID: 19019609
[TBL] [Abstract][Full Text] [Related]
5. Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products.
Fruijtier-Pölloth C
Toxicology; 2005 Oct; 214(1-2):1-38. PubMed ID: 16011869
[TBL] [Abstract][Full Text] [Related]
6. Characterization of poly(ethylene glycol) and PEGylated products by LC/MS with postcolumn addition of amines.
Huang L; Gough PC; Defelippis MR
Anal Chem; 2009 Jan; 81(2):567-77. PubMed ID: 19072225
[TBL] [Abstract][Full Text] [Related]
7. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
8. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.
Balan S; Choi JW; Godwin A; Teo I; Laborde CM; Heidelberger S; Zloh M; Shaunak S; Brocchini S
Bioconjug Chem; 2007; 18(1):61-76. PubMed ID: 17226958
[TBL] [Abstract][Full Text] [Related]
9. Obstacles and pitfalls in the PEGylation of therapeutic proteins.
Gaberc-Porekar V; Zore I; Podobnik B; Menart V
Curr Opin Drug Discov Devel; 2008 Mar; 11(2):242-50. PubMed ID: 18283612
[TBL] [Abstract][Full Text] [Related]
10. Ultrafiltration characteristics of pegylated proteins.
Molek JR; Zydney AL
Biotechnol Bioeng; 2006 Oct; 95(3):474-82. PubMed ID: 16736533
[TBL] [Abstract][Full Text] [Related]
11. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
Ivens IA; Achanzar W; Baumann A; Brändli-Baiocco A; Cavagnaro J; Dempster M; Depelchin BO; Rovira AR; Dill-Morton L; Lane JH; Reipert BM; Salcedo T; Schweighardt B; Tsuruda LS; Turecek PL; Sims J
Toxicol Pathol; 2015 Oct; 43(7):959-83. PubMed ID: 26239651
[TBL] [Abstract][Full Text] [Related]
12. Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins.
Zhao H; Yang K; Martinez A; Basu A; Chintala R; Liu HC; Janjua A; Wang M; Filpula D
Bioconjug Chem; 2006; 17(2):341-51. PubMed ID: 16536464
[TBL] [Abstract][Full Text] [Related]
13. Triethylene glycol HO(CH2CH2O)3H.
Ballantyne B; Snellings WM
J Appl Toxicol; 2007; 27(3):291-9. PubMed ID: 17299811
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins.
Fee CJ; Van Alstine JM
Bioconjug Chem; 2004; 15(6):1304-13. PubMed ID: 15546197
[TBL] [Abstract][Full Text] [Related]
15. Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules.
Fee CJ
Biotechnol Bioeng; 2007 Nov; 98(4):725-31. PubMed ID: 17461424
[TBL] [Abstract][Full Text] [Related]
16. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
Wang X; Ishida T; Kiwada H
J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
18. Disulfide bridge based PEGylation of proteins.
Brocchini S; Godwin A; Balan S; Choi JW; Zloh M; Shaunak S
Adv Drug Deliv Rev; 2008 Jan; 60(1):3-12. PubMed ID: 17920720
[TBL] [Abstract][Full Text] [Related]
19. Intermolecular interaction of avidin and PEGylated biotin.
Ke S; Wright JC; Kwon GS
Bioconjug Chem; 2007; 18(6):2109-14. PubMed ID: 17944528
[TBL] [Abstract][Full Text] [Related]
20. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
